Best Life Sciences Companies in Ann Arbor, United States
The 89 best Life Sciences companies in Ann Arbor, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: HistoSonics.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Ann Arbor
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HistoSonics Ultrasound-based tissue ablation 69Funding top 17%Patents top 17%Innovation top 19%News top 23% All 11 signals ▾Fundingtop 17% Patentstop 17% Innovationtop 19% Newstop 23% Producttop 26% Moattop 26% Growthtop 30% Techtop 46% Talentbottom 49% Marketbottom 42% Globalbottom 40% Funding: Raised $316M across 11 rounds · 11 rounds over 12 yrs (0.9/yr) Patents: 168 patents matched (strict assignee match) · 108 filings since 2022 vs 24 in 2017-21 rank vs industry peers · Fliar Intelligence Index 69/100 | $316M | 8 mo ago | 56 | 2009 | Mike Blue President and CEO | WordPressMySQLSalesforce+33 | 168 patents Image-guided therapeutic ultrasound (histotripsy) systems for non-invasive tissue ablation | — |
| 2 | ONL Therapeutics Developer of small peptide molecule to prevent the death of photoreceptor cells | $146M | 21 mo ago | 29 | 2011 | — | WordPress Site EditorWordPressMySQL+19 | — | — |
| 3 | Strata Oncology Precision oncology company enabling smarter cancer treatment through advanced biomarker algorithms | $133M | 19 mo ago | 125 | 2015 | Scott Tomlins Co-Founder | — | 19 patents AI-driven genomic biomarkers for predicting cancer therapy and immune checkpoint efficacy | — |
| 4 | Esperion Therapeutics Developer of lipoprotein cholesterol (LDL-C) lowering therapies | $130M | 61 mo ago | 240 240 → 347 (+45%) | 1998 | — | DrupalPHPBootstrap+20 | 349 patents Patents concentrated in health & consumer products | 1 job opening · 1 launch |
| 5 | Millendo Therapeutics Developer of immune-mediated targeted cancer therapies | $128M | 101 mo ago | 30 | 2012 | — | — | — | — |
| 6 | BlueWillow Biologics Pioneering intranasal vaccines for infectious disease and pandemic preparedness | $104M | 28 mo ago | 9 | 1996 | Chad Costley Chief Executive Officer | WordPressMySQLPHP+20 | 25 patents Nanoemulsion-based vaccine and antimicrobial delivery systems for mucosal and injectable use | — |
| 7 | QuatRx Pharmaceutical company focused on compounds in the endocrine and metabolic therapeutic areas | $91M | 205 mo ago | 5 | 2000 | Robert Zerbe CEO | — | — | — |
| 8 | NeuMoDx Developer of a platform for low cost molecular testing | $66M | 97 mo ago | 125 | 2012 | — | — | — | — |
| 9 | Lycera Development of small-molecule immunomodulators for the treatment of patients with autoimmune diseases. | $65M | 132 mo ago | 22 | 2006 | — | — | 218 patents Small‑molecule RORγ and ROCK modulators for inflammatory, autoimmune and cancer therapies | — |
| 10 | AVS Pulse Developer of a medical device to treat severely calcified arterial disease | $57M | 20 mo ago | 7 | 2017 | Robert Chisena Co-Founder & CTO | WordPress Block EditorWordPressMySQL+19 | — | 2 job openings |
| 11 | Therapeutic Systems Research Laboratories Preclinical CRO driving smarter drug development with integrated services and scientific clarity 32Funding top 37%Innovation top 39%Product top 46%Talent bottom 49% All 7 signals ▾Fundingtop 37% Innovationtop 39% Producttop 46% Talentbottom 49% Techbottom 44% Globalbottom 29% Marketbottom 28% Funding: Raised $51.6M across 32 rounds · 32 rounds over 23 yrs (1.4/yr) Innovation: 9 product lines rank vs industry peers · Fliar Intelligence Index 32/100 | $52M | 13 mo ago | 20 | 1997 | Elke Lipka President and CEO | Squarespace CommerceSquarespaceTypeScript+12 | — | — |
| 12 | CytoPherx Cytopheresis systems for inflammatory conditions | $48M | 173 mo ago | — | 1994 | Charles Fisher CEO | — | 46 patents Extracorporeal cytopheresis cartridges for targeted cell removal and cardiac function enhancement | — |
| 13 | Genomenon Provider of software, data, and services for genomic information analysis | $37M | 25 mo ago | 68 | 2014 | — | WebflowAmazon Web ServicesreCAPTCHA+16 | — | — |
| 14 | Swift Biosciences Develops and sells reagents for genetic testing and Next Generation Sequencing (NGS). | $35M | 91 mo ago | 41 | 2010 | — | — | 111 patents Optimized NGS library preparation: polymerases, adapters, normalization, and targeted amplification. | — |
| 15 | Sling Therapeutics Developer of therapeutics for the treatment of autoimmune and rare diseases | $35M | 48 mo ago | 18 | 2020 | — | WordPress Block EditorWordPressMySQL+19 | — | — |
| 16 | Accuri Cytometers Cell Analysis Flow Cytometers | $31M | 191 mo ago | 13 | 2004 | — | — | 53 patents Automated plate handling, data acquisition, and networking for flow cytometry instruments | — |
| 17 | Hygieia Provider of insulin dosage and medication guidance system | $29M | 64 mo ago | 17 | 2007 | — | — | 93 patents Automated insulin dosing optimization and glucose monitoring for diabetes management | — |
| 18 | Akadeum Life Sciences Provider of a technology platform for cell sorting | $26M | 14 mo ago | 26 26 → 16 (-38%) | 2014 | Brandon McNaughton Chief Executive Officer & Co-Founder | Cart FunctionalityWooCommerceWordPress+24 | — | — |
| 19 | Tangent Medical Developer of intravenous catheters and related IV therapy products | $23M | 128 mo ago | 11 | 2009 | — | — | — | — |
| 20 | Enumera Molecular Developer of liquid biopsy tools | $19M | 49 mo ago | 21 | 2022 | Matthew Cooper CEO | — | 28 patents Digital image analysis and quantitative cell‑free DNA/Nucleic‑acid detection technologies. | — |
| 21 | Everist Health Technology to measure endothelial function | $13M | 165 mo ago | — | 2002 | Steve Everist Co-Founder & CTO | — | — | — |
| 22 | Rubicon Genomics Provider of reagents and kits for pre-analytical amplification technologies | $13M | 131 mo ago | 33 | 2000 | — | — | 68 patents DNA library preparation, barcoding, and methylation analysis via multiplexed amplification | — |
| 23 | Upkara Developer of a biopreservation technology for therapeutics, vaccines and reagents | $13M | 37 mo ago | 13 13 → 22 (+69%) | 2014 | Pravansu Mohanty Founder | — | 42 patents Cryopreservation and ambient-temperature storage of bioactive lipid formulations | — |
| 24 | NeuroNexus Advanced electrophysiology solutions for neuroscience research, instrumentation, and software | $12M | 15 mo ago | 37 37 → 34 (-8%) | 2004 | — | WordPressMySQLPHP+31 | 90 patents Implantable high‑density, flexible silicon‑carbide neural electrode arrays and 3D lead systems | 3 launchs |
| 25 | Phenomics Health AI-based precision medicine solution for providers | $12M | 43 mo ago | 3 | 2018 | Brian Athey Co-Founder & CTO | WordPress Block EditorWordPressMySQL+17 | — | — |
| 26 | H3D High-performance imaging spectrometers revolutionizing gamma-ray source identification and localization 35AI top 15%Patents top 46%Funding top 49%Talent bottom 49% All 9 signals ▾AItop 15% Patentstop 46% Fundingtop 49% Talentbottom 49% Productbottom 48% Globalbottom 41% Marketbottom 39% Innovationbottom 39% Techbottom 35% AI: Holds AI/ML patents (G06N-family CPC) Patents: 19 patents matched (strict assignee match) · 6 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 35/100 | $10M | 6 mo ago | 31 | 2011 | Weiyi Wang Research And Development Director | Apple iCloud MailUbuntuYouTube+4 | 19 patents Coded-aperture radiation imaging and 3D source localization systems | 1 launch |
| 27 | Aquaro Histology Developer of automated section mounting system for histology | $10M | 103 mo ago | 12 | 2013 | Vincent A Alessi Co-Founder & CSO | — | 8 patents Automated slide mounting systems for biological specimen preparation in histology labs. | — |
| 28 | Truven Health Healthcare data, technology, and analytics solutions to drive progress in health | $8M | 135 mo ago | 54,912 | 2012 | — | — | — | — |
| 29 | NOTA Laboratories Provider of Nitric oxide-based therapies for chronic rhinosinusitis | $8M | 13 mo ago | 13 | 2014 | Mark Meyerhoff Co-Founder & CTO | — | — | — |
| 30 | DNA Software PCR assay design software and services for life-changing organizations | $7M | 182 mo ago | 18 | 2000 | — | WordPressMySQLPHP+24 | — | — |
| 31 | Compendia Bioscience Informatics solutions for cancer research, variant prioritization, and reporting | $6M | 190 mo ago | 34 | 2006 | — | — | — | — |
| 32 | EVOQ Therapeutics Nano-vaccines for cancer immunotherapy | $5M | 21 mo ago | 7 | 2016 | — | Wix eCommerceWixSentry+13 | — | — |
| 33 | Resonant Therapeutics Developer of antibody therapeutics to treat cancer | $5M | 21 mo ago | 5 | 2014 | — | — | — | — |
| 34 | Blue Arbor Technologies Provider of prosthetic rehabilitation after limb loss 22Talent top 38%Funding bottom 48%Market bottom 37%Global bottom 25% All 4 signals ▾Talenttop 38% Fundingbottom 48% Marketbottom 37% Globalbottom 25% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $5.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 22/100 | $5M | 3 mo ago | — | 2023 | Alex Vaskov Co-Founder & CTO | — | — | — |
| 35 | Epsilon Imaging Advanced echo analysis software solutions improving cardiovascular care and workflow | $5M | 131 mo ago | 13 | 2008 | Eric Sieczka Chairman | — | — | — |
| 36 | Xoran Technologies Innovating low-dose CT imaging solutions for human and veterinary point-of-care | $4M | 80 mo ago | 61 61 → 49 (-20%) | 2001 | — | WordPressMySQLPHP+27 | 43 patents Advanced CT imaging hardware and motion‑correction technologies for patient‑centric diagnostics | 1 launch |
| 37 | Gema Diagnostics Develops non-invasive solutions for better vitro fertilization (IVF) outcomes. | $3M | 158 mo ago | — | 2005 | Diogo Melo Co-founder | — | — | — |
| 38 | First Wave Bio Developer of therapeutics for treating inflammatory bowel disease | $3M | 29 mo ago | 10 | 2015 | Luigi Franchi Co-Founder | — | — | — |
| 39 | Compendia Bioscience Compendia Bioscience offers genomic data and analysis tools for biomarker and gene target discoveries with a… | $2M | 224 mo ago | 75,000 | 1956 | Srinath Venkatesh Managing Director & VP/GM- India and South Asia | Adobe Experience ManagerApple iCloud MailJava+20 | — | — |
| 40 | Peptinovo Biopharma Developer of therapeutics for cancer treatment | $2M | 21 mo ago | 3 | 2018 | Bill Elliott Co-Founder | — | 30 patents Lipid-based drug delivery systems and vitamin E (tocotrienol) synthesis for oncology therapeutics | — |
| 41 | 3D Biomatrix Spheroid cultures for cancer research, stem cell research, and drug discovery. | $2M | 155 mo ago | 7 | 2009 | Mahendra Ramsinghani Co-Founder | — | 6 patents Microfluidic hanging-drop platforms for 3D cell culture and spheroid formation | — |
| 42 | Diapin Therapeutics Developing novel therapies for cardiovascular and metabolic diseases | $2M | 106 mo ago | — | 2011 | Bruce Markham CEO & President | — | — | 3 awards |
| 43 | Steltechnologies Provider of financial management, credit, debt, and housing counseling services | $1M | 134 mo ago | 3 | 2013 | — | — | — | — |
| 44 | iReprogram Provider of a bioinformatics platform for the development of precision medicine | $781K | 64 mo ago | 8 | 2017 | Christian Macedonia CEO | — | — | — |
| 45 | Parabricks NVIDIA: AI computing leader, powering innovation across industries | $748K | 92 mo ago | 5 | 2016 | — | — | — | — |
| 46 | LifeMagnetics Developer of new ferrofluidic nanomaterials | $429K | 101 mo ago | 6 | 2013 | — | — | — | — |
| 47 | Soundbites Hearing preservation through innovative ACEMg formula, addressing hearing loss and related conditions | $375K | 182 mo ago | 3 | 2010 | — | Cart FunctionalityShopifySentry+23 | — | — |
| 48 | PROMISEVISION 3D Provider of dental microscope technology | $325K | 100 mo ago | — | 2009 | — | — | — | — |
| 49 | Endra Life Sciences Developer of ultrasound imaging technology for liver disease detection | $287K | 8 mo ago | 21 | 2007 | Francois Michelon CEO | DudaNginxSnowplow Analytics+11 | 188 patents Thermoacoustic medical imaging probes and RF applicators for enhanced diagnostic imaging | — |
| 50 | siRNAx US-based, early-stage biotech developing siRNA therapeutics for rare lymphomas | $220K | 144 mo ago | — | 2012 | Michael Garavito Co-Founder & CSO | — | 3 patents Cytokine-fusion protein vectors for targeted siRNA delivery into cells and tissues | — |
Top 12 Life Sciences companies in Ann Arbor
#1
Acquired · Ann Arbor, Michigan · founded 2009 · 56 employees$315.7Mraised▾
HistoSonics is developing Histotripsy technology, licensed from the University of Michigan. It is a non-invasive, image guided therapeutic ultrasound system that excises tissue. Uses pulsed sound waves to induce cavitation that mechanically destroys tissue, tumors and plaque at the cellular level. Application areas include cardiovascular, oncology, neurology and urology.
- Oct 2025Series E$250M
- Jul 2024Series D$102M
- Dec 2022Series D$85M
- Nov 2020Conventional Debt$15M
#2
Series A · Ann Arbor, Michigan · founded 2011 · 31 employees$10.1Mraised▾
High-performance imaging spectrometers revolutionizing gamma-ray source identification and localization. The company specializes in advanced radiation detection technology, offering solutions for nuclear power, CBRNE defense, waste management, safeguards, medical applications, and environmental monitoring. They provide imaging spectrometers, spectrometers, handheld directional RIIDs, and custom systems. Their cutting-edge CZT technology enables fast startup, compact design, industry-leading energy resolution, efficient imaging, and a user-friendly interface. They focus on customer needs, offering complete solutions for identifying, quantifying, and localizing sources. Their products are used in nuclear power plants and by emergency responders worldwide. They offer hardware and software solutions, including SourceTerm RMS. The company's technology supports various applications, including nuclear power plant contamination cleanup, CBRNE response, environmental monitoring, defense, and medical imaging.
- Dec 2025Grant (prize money)$1.4M
- Jul 2024Grant (prize money)$206.5K
- Jun 2022Grant (prize money)$1.4M
- Jun 2021Grant (prize money)$1.4M
#3
Series A · Ann Arbor, Michigan · founded 2023$5Mraised▾
Provider of prosthetic rehabilitation solutions after limb loss, with a focus on neuromuscular interfaces and robotic technology. It is designed to detect voluntary nerve and muscle control signals to facilitate naturalistic function of upper limb prosthetics. It consists of implantable intramuscular electrodes, a sensing unit, a socket mounted receiver, and software for controlling the system
- Feb 2026Series A$5M
#4
Funding Raised · Ann Arbor, Michigan · founded 1997 · 20 employees$51.6Mraised▾
Preclinical CRO driving smarter drug development with integrated services and scientific clarity. Focused on helping pharmaceutical, biotech, and academic teams advance early drug candidates. They offer integrated support across formulation development, bioanalysis, PK/ADME, toxicology, drug delivery technologies, and strategic consulting. Services are customized to meet timelines and therapeutic needs. They provide tailored approaches to improve solubility, enhance stability, and meet delivery requirements. High-sensitivity drug quantification using HPLC and LC-MS/MS is used for pharmacokinetic, safety, and toxicology studies. Planning and guidance are offered to close knowledge gaps, align with regulatory needs, and support clear decision-making. Studies are designed to assess how compounds are absorbed, distributed, metabolized, and eliminated, along with early insights into toxicology. Support is available for novel delivery systems including MAP technology. They combine scientific insight with practical experience to help move programs forward, guided by collaboration, transparency, and a strong track record in early development.
- May 2025Grant (prize money)$1.6M
- Mar 2025Grant (prize money)$299.6K
- Mar 2025Grant (prize money)$6M
- Aug 2023Grant (prize money)$1.3M
#5
Series C · Ann Arbor, Michigan · founded 2015 · 125 employees$133Mraised▾
Precision oncology company enabling smarter cancer treatment through advanced biomarker algorithms. The company focuses on next-generation precision oncology, developing predictive diagnostic tools for cancer treatment. They offer innovative solutions like Antibody-drug Conjugate Treatment Response Scores and Immunotherapy Response Score, utilizing proprietary calculation methods and algorithms. These tools aim to predict patient response to therapies, ensuring individuals receive the most effective treatment. The company's approach combines tumor biology and microenvironment analysis, incorporating factors like tumor mutation burden and protein expression. They strive to accelerate the impact of precision medicine, offering advanced algorithmic biomarkers for antibody drug conjugates and immunotherapy. The company is committed to improving cancer care through scientific innovation and data-driven decision-making. This is a B2B, SaaS, and tech company in the healthcare sector.
- Nov 2024Series C$6.1M
- Jul 2021Series C$90M
- Nov 2020Series B$5M
- May 2018Series B$26M
#6
Series D · Ann Arbor, Michigan · founded 2011 · 29 employees$146.2Mraised▾
ONL Therapeutics is a developer of small peptide molecules to prevent the death of photoreceptor cells. It is developing therapies for eye-related disorders using its technology. Its technology is focused on preventing the death of key retinal cells, including photoreceptors which are the root cause of vision loss and the leading cause of blindness. Its lead product ONL-1204 is a small molecule peptide which inhibits the Fas pathway that induces apoptosis. Its preclinical in-vivo data claims to have supported the potential application in retinal detachment, age-related macular degeneration (AMD) and other chronic retinal diseases.
- Sep 2024Series D$65M
- Feb 2024Series C$10M
- Mar 2023Series C$15M
- Dec 2020Series B$46.9M
#7
Series C · Ann Arbor, Michigan · founded 2014 · 26 employees$26.1Mraised▾
Provider of a technology platform for cell sorting. The company offers a microbubble cell separation platform by using Cell Separation and Buoyancy Activated Cell Sorting (BACS) technology which is used in purifying cells from blood and tissues for research or diagnostics areas.
- Apr 2025Series C$20M
- May 2023Series B$6M
- Oct 2021Series B$17.5M
- Dec 2019Series A—
#8
Acquired · Ann Arbor, Michigan · founded 2017 · 7 employees$56.9Mraised▾
Developer of a medical device to treat severely calcified arterial disease. The company develops pulsatile intravascular lithotripsy (PIVL), a therapy device that is delivered through a balloon-based platform called PULSE IVL System to restore blood flow to blockages in the legs caused by severe calcium buildup.
- Oct 2024Series B$36M
- Apr 2023Series B$8.8M
- Jan 2023Series B$20M
- Oct 2022Series A$4.4M
#9
Seed · Ann Arbor, Michigan · founded 2014 · 13 employees$7.5Mraised▾
Provider of Nitric oxide-based therapies for chronic rhinosinusitis. The technology increases the production of nitric oxide that provides natural antimicrobial action in the sinus airways and maintains the antimicrobial and antiviral equilibrium to fight infections. It is applicable for other disorders related to respiratory tract infections such as COPD and cystic fibrosis.
- Apr 2025Grant (prize money)$1.7M
- Apr 2022Seed—
- Apr 2022Grant (prize money)—
- Sep 2019Grant (prize money)$1.7M
#10
Acquired · Ann Arbor, Michigan · founded 2004 · 37 employees$11.6Mraised▾
Advanced electrophysiology solutions for neuroscience research, instrumentation, and software. The company pioneers cutting-edge neural interface technologies, instrumentation systems, and analytical software, streamlining neuroscience research globally. They innovate and deliver tools for simplified research, focusing on advanced multi-channel electrodes and integrated electrophysiology solutions. Their offerings include a wide range of electrode designs, high-performance instrumentation, and leading-edge software. They develop customer-driven products backed by neuroscientists and neural engineers. The company provides world-class neural interface products, brain-centered systems, and analytics. They are committed to innovation, drive, resilience, collaboration, integrity, and excellence. Their products support electrophysiology research laboratories across the globe. They focus on developing solutions that streamline complex heart, brain, and nervous system research.
- Feb 2025Grant (prize money)$449.2K
- Sep 2020Grant (prize money)$242.4K
- Aug 2013Grant (prize money)$3M
- Jun 2011Grant (prize money)$3M
#11
Series C · Ann Arbor, Michigan · founded 1996 · 9 employees$103.7Mraised▾
Pioneering intranasal vaccines for infectious disease and pandemic preparedness. The company is a clinical-stage biotechnology innovator focused on transforming prevention and treatment through its advanced intranasal delivery platform. Their technology aims to combat infectious diseases, enhance pandemic preparedness, and address food allergies. The platform utilizes novel oil-in-water emulsion droplets to stimulate a robust mucosal, systemic, and cellular immune response. This unique vaccine technology is compatible with a broad range of antigens and facilitates enhanced permeation of the nasal mucosa. The company is dedicated to advancing intranasal vaccine technology for improved global health outcomes. The company is focused on research and development, clinical trials, and strategic partnerships to realize the full potential of its platform.
- Jan 2024Series C$850K
- Oct 2022Series C$5.9M
- Sep 2020Grant (prize money)$2.9M
- Apr 2020Series C$8.2M
#12
Series B · Ann Arbor, Michigan · founded 2014 · 68 employees$36.8Mraised▾
Provider of software, data, and services for genomic information analysis. The company offers platforms for germline and somatic variant interpretation. It facilitates access to article information on variants and curated germline variant content. The cancer knowledgebase interprets cancer variants, connecting them to therapies and clinical trials.
- May 2024Series B$5.5M
- Mar 2022Series B$20M
- Feb 2022Grant (prize money)$1.7M
- Mar 2021Series B$5.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.